Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Identifieur interne : 004019 ( Ncbi/Curation ); précédent : 004018; suivant : 004020Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Auteurs : Meletios A. Dimopoulos [Grèce] ; Judith Trotman [Australie] ; Alessandra Tedeschi [Italie] ; Jeffrey V. Matous [États-Unis] ; David Macdonald [Canada] ; Constantine Tam [Australie] ; Olivier Tournilhac [France] ; Shuo Ma [États-Unis] ; Albert Oriol [Espagne] ; Leonard T. Heffner [États-Unis] ; Chaim Shustik [Canada] ; Ram N García-Sanz [Espagne] ; Robert F. Cornell [États-Unis] ; Carlos Fernández De Larrea [Espagne] ; Jorge J. Castillo [États-Unis] ; Miquel Granell [Espagne] ; Marie-Christine Kyrtsonis [Grèce] ; Veronique Leblond [France] ; Argiris Symeonidis [Grèce] ; Efstathios Kastritis [Grèce] ; Priyanka Singh [États-Unis] ; Jianling Li [États-Unis] ; Thorsten Graef [États-Unis] ; Elizabeth Bilotti [États-Unis] ; Steven Treon [États-Unis] ; Christian Buske [Allemagne]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Femelle, Humains, Macroglobulinémie de Waldenström (anatomopathologie), Macroglobulinémie de Waldenström (traitement médicamenteux), Mâle, Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Pyrazoles (administration et posologie), Pyrimidines (administration et posologie), Rituximab (administration et posologie), Résistance aux médicaments antinéoplasiques (), Stade de la tumeur, Sujet âgé, Taux de survie, Thérapie de rattrapage, Études de suivi.
- MESH :
- administration et posologie : Pyrazoles, Pyrimidines, Rituximab.
- anatomopathologie : Macroglobulinémie de Waldenström.
- traitement médicamenteux : Macroglobulinémie de Waldenström.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Pronostic, Résistance aux médicaments antinéoplasiques, Stade de la tumeur, Sujet âgé, Taux de survie, Thérapie de rattrapage, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Drug Resistance, Neoplasm (drug effects), Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Pyrazoles (administration & dosage), Pyrimidines (administration & dosage), Rituximab (administration & dosage), Salvage Therapy, Survival Rate, Waldenstrom Macroglobulinemia (drug therapy), Waldenstrom Macroglobulinemia (pathology).
- MESH :
- chemical , administration & dosage : Pyrazoles, Pyrimidines, Rituximab.
- drug effects : Drug Resistance, Neoplasm.
- drug therapy : Waldenstrom Macroglobulinemia.
- pathology : Waldenstrom Macroglobulinemia.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Salvage Therapy, Survival Rate.
Abstract
In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease.
DOI: 10.1016/S1470-2045(16)30632-5
PubMed: 27956157
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001158
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001155
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001155
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004019
Links to Exploration step
pubmed:27956157Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.</title>
<author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name>
<affiliation wicri:level="3"><nlm:affiliation>National and Kapodistrian University of Athens School of Medicine, Athens, Greece. Electronic address: mdimop@med.uoa.gr.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>National and Kapodistrian University of Athens School of Medicine, Athens</wicri:regionArea>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trotman, Judith" sort="Trotman, Judith" uniqKey="Trotman J" first="Judith" last="Trotman">Judith Trotman</name>
<affiliation wicri:level="4"><nlm:affiliation>Concord Hospital, University of Sydney, Concord, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Concord Hospital, University of Sydney, Concord, NSW</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tedeschi, Alessandra" sort="Tedeschi, Alessandra" uniqKey="Tedeschi A" first="Alessandra" last="Tedeschi">Alessandra Tedeschi</name>
<affiliation wicri:level="3"><nlm:affiliation>Niguarda Ca' Granda Hospital, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Niguarda Ca' Granda Hospital, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Matous, Jeffrey V" sort="Matous, Jeffrey V" uniqKey="Matous J" first="Jeffrey V" last="Matous">Jeffrey V. Matous</name>
<affiliation wicri:level="2"><nlm:affiliation>Colorado Blood Cancer Institute, Denver, CO, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Colorado Blood Cancer Institute, Denver, CO</wicri:regionArea>
<placeName><region type="state">Colorado</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Macdonald, David" sort="Macdonald, David" uniqKey="Macdonald D" first="David" last="Macdonald">David Macdonald</name>
<affiliation wicri:level="1"><nlm:affiliation>Dalhousie University, Halifax, NS, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Dalhousie University, Halifax, NS</wicri:regionArea>
<wicri:noRegion>NS</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tam, Constantine" sort="Tam, Constantine" uniqKey="Tam C" first="Constantine" last="Tam">Constantine Tam</name>
<affiliation wicri:level="1"><nlm:affiliation>Peter MacCallum Cancer Centre and St Vincent's Hospital, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Peter MacCallum Cancer Centre and St Vincent's Hospital, Melbourne, VIC</wicri:regionArea>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tournilhac, Olivier" sort="Tournilhac, Olivier" uniqKey="Tournilhac O" first="Olivier" last="Tournilhac">Olivier Tournilhac</name>
<affiliation wicri:level="3"><nlm:affiliation>Hématologie Clinique Adulte et Thérapie Cellulaire, CHU de Clermont-Ferrand, Clermont-Ferrand, France; EA 7283, Universite d'Auvergne, Clermont-Ferrand, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hématologie Clinique Adulte et Thérapie Cellulaire, CHU de Clermont-Ferrand, Clermont-Ferrand, France; EA 7283, Universite d'Auvergne, Clermont-Ferrand</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Auvergne (région administrative)</region>
<settlement type="city">Clermont-Ferrand</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ma, Shuo" sort="Ma, Shuo" uniqKey="Ma S" first="Shuo" last="Ma">Shuo Ma</name>
<affiliation wicri:level="2"><nlm:affiliation>Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oriol, Albert" sort="Oriol, Albert" uniqKey="Oriol A" first="Albert" last="Oriol">Albert Oriol</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Heffner, Leonard T" sort="Heffner, Leonard T" uniqKey="Heffner L" first="Leonard T" last="Heffner">Leonard T. Heffner</name>
<affiliation wicri:level="2"><nlm:affiliation>Winship Cancer Institute of Emory University, Atlanta, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Winship Cancer Institute of Emory University, Atlanta, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shustik, Chaim" sort="Shustik, Chaim" uniqKey="Shustik C" first="Chaim" last="Shustik">Chaim Shustik</name>
<affiliation wicri:level="1"><nlm:affiliation>Royal Victoria Hospital at McGill University Health Centre, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Royal Victoria Hospital at McGill University Health Centre, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Garcia Sanz, Ram N" sort="Garcia Sanz, Ram N" uniqKey="Garcia Sanz R" first="Ram N" last="García-Sanz">Ram N García-Sanz</name>
<affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Universitario de Salamanca, Salamanca</wicri:regionArea>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cornell, Robert F" sort="Cornell, Robert F" uniqKey="Cornell R" first="Robert F" last="Cornell">Robert F. Cornell</name>
<affiliation wicri:level="2"><nlm:affiliation>Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vanderbilt-Ingram Cancer Center, Nashville, TN</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Larrea, Carlos Fernandez" sort="De Larrea, Carlos Fernandez" uniqKey="De Larrea C" first="Carlos Fernández" last="De Larrea">Carlos Fernández De Larrea</name>
<affiliation wicri:level="3"><nlm:affiliation>Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clínic de Barcelona, IDIBAPS, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Castillo, Jorge J" sort="Castillo, Jorge J" uniqKey="Castillo J" first="Jorge J" last="Castillo">Jorge J. Castillo</name>
<affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Granell, Miquel" sort="Granell, Miquel" uniqKey="Granell M" first="Miquel" last="Granell">Miquel Granell</name>
<affiliation wicri:level="3"><nlm:affiliation>Hospital Sant Pau, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Sant Pau, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kyrtsonis, Marie Christine" sort="Kyrtsonis, Marie Christine" uniqKey="Kyrtsonis M" first="Marie-Christine" last="Kyrtsonis">Marie-Christine Kyrtsonis</name>
<affiliation wicri:level="3"><nlm:affiliation>National and Kapodistrian University of Athens School of Medicine, Athens, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>National and Kapodistrian University of Athens School of Medicine, Athens</wicri:regionArea>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leblond, Veronique" sort="Leblond, Veronique" uniqKey="Leblond V" first="Veronique" last="Leblond">Veronique Leblond</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Pitié-Salpêtrière APHP, UPMC Université Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Pitié-Salpêtrière APHP, UPMC Université Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Symeonidis, Argiris" sort="Symeonidis, Argiris" uniqKey="Symeonidis A" first="Argiris" last="Symeonidis">Argiris Symeonidis</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Patras Medical School, Patras, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>University of Patras Medical School, Patras</wicri:regionArea>
<wicri:noRegion>Patras</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kastritis, Efstathios" sort="Kastritis, Efstathios" uniqKey="Kastritis E" first="Efstathios" last="Kastritis">Efstathios Kastritis</name>
<affiliation wicri:level="3"><nlm:affiliation>National and Kapodistrian University of Athens School of Medicine, Athens, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>National and Kapodistrian University of Athens School of Medicine, Athens</wicri:regionArea>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Singh, Priyanka" sort="Singh, Priyanka" uniqKey="Singh P" first="Priyanka" last="Singh">Priyanka Singh</name>
<affiliation wicri:level="2"><nlm:affiliation>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Jianling" sort="Li, Jianling" uniqKey="Li J" first="Jianling" last="Li">Jianling Li</name>
<affiliation wicri:level="2"><nlm:affiliation>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Graef, Thorsten" sort="Graef, Thorsten" uniqKey="Graef T" first="Thorsten" last="Graef">Thorsten Graef</name>
<affiliation wicri:level="2"><nlm:affiliation>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bilotti, Elizabeth" sort="Bilotti, Elizabeth" uniqKey="Bilotti E" first="Elizabeth" last="Bilotti">Elizabeth Bilotti</name>
<affiliation wicri:level="2"><nlm:affiliation>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Treon, Steven" sort="Treon, Steven" uniqKey="Treon S" first="Steven" last="Treon">Steven Treon</name>
<affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Buske, Christian" sort="Buske, Christian" uniqKey="Buske C" first="Christian" last="Buske">Christian Buske</name>
<affiliation wicri:level="3"><nlm:affiliation>Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:27956157</idno>
<idno type="pmid">27956157</idno>
<idno type="doi">10.1016/S1470-2045(16)30632-5</idno>
<idno type="wicri:Area/PubMed/Corpus">001158</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001158</idno>
<idno type="wicri:Area/PubMed/Curation">001155</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001155</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001155</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001155</idno>
<idno type="wicri:Area/Ncbi/Merge">004019</idno>
<idno type="wicri:Area/Ncbi/Curation">004019</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.</title>
<author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name>
<affiliation wicri:level="3"><nlm:affiliation>National and Kapodistrian University of Athens School of Medicine, Athens, Greece. Electronic address: mdimop@med.uoa.gr.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>National and Kapodistrian University of Athens School of Medicine, Athens</wicri:regionArea>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trotman, Judith" sort="Trotman, Judith" uniqKey="Trotman J" first="Judith" last="Trotman">Judith Trotman</name>
<affiliation wicri:level="4"><nlm:affiliation>Concord Hospital, University of Sydney, Concord, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Concord Hospital, University of Sydney, Concord, NSW</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tedeschi, Alessandra" sort="Tedeschi, Alessandra" uniqKey="Tedeschi A" first="Alessandra" last="Tedeschi">Alessandra Tedeschi</name>
<affiliation wicri:level="3"><nlm:affiliation>Niguarda Ca' Granda Hospital, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Niguarda Ca' Granda Hospital, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Matous, Jeffrey V" sort="Matous, Jeffrey V" uniqKey="Matous J" first="Jeffrey V" last="Matous">Jeffrey V. Matous</name>
<affiliation wicri:level="2"><nlm:affiliation>Colorado Blood Cancer Institute, Denver, CO, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Colorado Blood Cancer Institute, Denver, CO</wicri:regionArea>
<placeName><region type="state">Colorado</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Macdonald, David" sort="Macdonald, David" uniqKey="Macdonald D" first="David" last="Macdonald">David Macdonald</name>
<affiliation wicri:level="1"><nlm:affiliation>Dalhousie University, Halifax, NS, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Dalhousie University, Halifax, NS</wicri:regionArea>
<wicri:noRegion>NS</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tam, Constantine" sort="Tam, Constantine" uniqKey="Tam C" first="Constantine" last="Tam">Constantine Tam</name>
<affiliation wicri:level="1"><nlm:affiliation>Peter MacCallum Cancer Centre and St Vincent's Hospital, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Peter MacCallum Cancer Centre and St Vincent's Hospital, Melbourne, VIC</wicri:regionArea>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tournilhac, Olivier" sort="Tournilhac, Olivier" uniqKey="Tournilhac O" first="Olivier" last="Tournilhac">Olivier Tournilhac</name>
<affiliation wicri:level="3"><nlm:affiliation>Hématologie Clinique Adulte et Thérapie Cellulaire, CHU de Clermont-Ferrand, Clermont-Ferrand, France; EA 7283, Universite d'Auvergne, Clermont-Ferrand, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hématologie Clinique Adulte et Thérapie Cellulaire, CHU de Clermont-Ferrand, Clermont-Ferrand, France; EA 7283, Universite d'Auvergne, Clermont-Ferrand</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Auvergne (région administrative)</region>
<settlement type="city">Clermont-Ferrand</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ma, Shuo" sort="Ma, Shuo" uniqKey="Ma S" first="Shuo" last="Ma">Shuo Ma</name>
<affiliation wicri:level="2"><nlm:affiliation>Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oriol, Albert" sort="Oriol, Albert" uniqKey="Oriol A" first="Albert" last="Oriol">Albert Oriol</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Heffner, Leonard T" sort="Heffner, Leonard T" uniqKey="Heffner L" first="Leonard T" last="Heffner">Leonard T. Heffner</name>
<affiliation wicri:level="2"><nlm:affiliation>Winship Cancer Institute of Emory University, Atlanta, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Winship Cancer Institute of Emory University, Atlanta, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shustik, Chaim" sort="Shustik, Chaim" uniqKey="Shustik C" first="Chaim" last="Shustik">Chaim Shustik</name>
<affiliation wicri:level="1"><nlm:affiliation>Royal Victoria Hospital at McGill University Health Centre, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Royal Victoria Hospital at McGill University Health Centre, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Garcia Sanz, Ram N" sort="Garcia Sanz, Ram N" uniqKey="Garcia Sanz R" first="Ram N" last="García-Sanz">Ram N García-Sanz</name>
<affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Universitario de Salamanca, Salamanca</wicri:regionArea>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cornell, Robert F" sort="Cornell, Robert F" uniqKey="Cornell R" first="Robert F" last="Cornell">Robert F. Cornell</name>
<affiliation wicri:level="2"><nlm:affiliation>Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vanderbilt-Ingram Cancer Center, Nashville, TN</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Larrea, Carlos Fernandez" sort="De Larrea, Carlos Fernandez" uniqKey="De Larrea C" first="Carlos Fernández" last="De Larrea">Carlos Fernández De Larrea</name>
<affiliation wicri:level="3"><nlm:affiliation>Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clínic de Barcelona, IDIBAPS, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Castillo, Jorge J" sort="Castillo, Jorge J" uniqKey="Castillo J" first="Jorge J" last="Castillo">Jorge J. Castillo</name>
<affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Granell, Miquel" sort="Granell, Miquel" uniqKey="Granell M" first="Miquel" last="Granell">Miquel Granell</name>
<affiliation wicri:level="3"><nlm:affiliation>Hospital Sant Pau, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Sant Pau, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kyrtsonis, Marie Christine" sort="Kyrtsonis, Marie Christine" uniqKey="Kyrtsonis M" first="Marie-Christine" last="Kyrtsonis">Marie-Christine Kyrtsonis</name>
<affiliation wicri:level="3"><nlm:affiliation>National and Kapodistrian University of Athens School of Medicine, Athens, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>National and Kapodistrian University of Athens School of Medicine, Athens</wicri:regionArea>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leblond, Veronique" sort="Leblond, Veronique" uniqKey="Leblond V" first="Veronique" last="Leblond">Veronique Leblond</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Pitié-Salpêtrière APHP, UPMC Université Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Pitié-Salpêtrière APHP, UPMC Université Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Symeonidis, Argiris" sort="Symeonidis, Argiris" uniqKey="Symeonidis A" first="Argiris" last="Symeonidis">Argiris Symeonidis</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Patras Medical School, Patras, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>University of Patras Medical School, Patras</wicri:regionArea>
<wicri:noRegion>Patras</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kastritis, Efstathios" sort="Kastritis, Efstathios" uniqKey="Kastritis E" first="Efstathios" last="Kastritis">Efstathios Kastritis</name>
<affiliation wicri:level="3"><nlm:affiliation>National and Kapodistrian University of Athens School of Medicine, Athens, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>National and Kapodistrian University of Athens School of Medicine, Athens</wicri:regionArea>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Singh, Priyanka" sort="Singh, Priyanka" uniqKey="Singh P" first="Priyanka" last="Singh">Priyanka Singh</name>
<affiliation wicri:level="2"><nlm:affiliation>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Jianling" sort="Li, Jianling" uniqKey="Li J" first="Jianling" last="Li">Jianling Li</name>
<affiliation wicri:level="2"><nlm:affiliation>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Graef, Thorsten" sort="Graef, Thorsten" uniqKey="Graef T" first="Thorsten" last="Graef">Thorsten Graef</name>
<affiliation wicri:level="2"><nlm:affiliation>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bilotti, Elizabeth" sort="Bilotti, Elizabeth" uniqKey="Bilotti E" first="Elizabeth" last="Bilotti">Elizabeth Bilotti</name>
<affiliation wicri:level="2"><nlm:affiliation>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Treon, Steven" sort="Treon, Steven" uniqKey="Treon S" first="Steven" last="Treon">Steven Treon</name>
<affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Buske, Christian" sort="Buske, Christian" uniqKey="Buske C" first="Christian" last="Buske">Christian Buske</name>
<affiliation wicri:level="3"><nlm:affiliation>Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Lancet. Oncology</title>
<idno type="eISSN">1474-5488</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Drug Resistance, Neoplasm (drug effects)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Prognosis</term>
<term>Pyrazoles (administration & dosage)</term>
<term>Pyrimidines (administration & dosage)</term>
<term>Rituximab (administration & dosage)</term>
<term>Salvage Therapy</term>
<term>Survival Rate</term>
<term>Waldenstrom Macroglobulinemia (drug therapy)</term>
<term>Waldenstrom Macroglobulinemia (pathology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Macroglobulinémie de Waldenström (anatomopathologie)</term>
<term>Macroglobulinémie de Waldenström (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Pyrazoles (administration et posologie)</term>
<term>Pyrimidines (administration et posologie)</term>
<term>Rituximab (administration et posologie)</term>
<term>Résistance aux médicaments antinéoplasiques ()</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Taux de survie</term>
<term>Thérapie de rattrapage</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Pyrazoles</term>
<term>Pyrimidines</term>
<term>Rituximab</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Pyrazoles</term>
<term>Pyrimidines</term>
<term>Rituximab</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Macroglobulinémie de Waldenström</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Neoplasm</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Waldenstrom Macroglobulinemia</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Waldenstrom Macroglobulinemia</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Macroglobulinémie de Waldenström</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Prognosis</term>
<term>Salvage Therapy</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Taux de survie</term>
<term>Thérapie de rattrapage</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004019 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004019 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:27956157 |texte= Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:27956157" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |